Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease

Authors:
Top Cited Papers
Publisher website
Google Scholar
Abstract
Background: A significant proportion of patients continue to experience cardiovascular (CV) events despite achieving recommended low‐density lipoprotein cholesterol (LDL‐C) targets, a phenomenon referred to as residual CV risk. Methods: Clinical evidence from large outcome trials highlights the impact of residual risk on cardiovascular disease (CVD) burden, underscoring the need for therapeutic strategies beyond LDL‐C lowering. Residual CV risk arises from diverse mechanisms, including persistent atherogenic dyslipidaemia [elevated triglyceride‐rich lipoproteins (TRL), high triglycerides (TG), low high‐density lipoprotein cholesterol (HDL‐C) levels and increased apolipoprotein B (ApoB), Lipoprotein(a) (Lp[a]) and non‐HDL‐C], chronic inflammation, metabolic disorders and a prothrombotic state. These abnormalities continue to drive atherosclerotic progression in optimally treated patients, underscoring that managing residual CV risk requires a multifaceted approach. Results: Lifestyle and dietary interventions remain foundational, targeting weight reduction, smoking cessation or adoption of a Mediterranean diet. Pharmacological options include statins (as first‐line therapy), or the use of ezetimibe, or bempedoic acid since they both have complementary effects to LDL‐C lowering. Emerging therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C‐III (ApoC3) and angiopoietin‐like 3 (ANGPTL3) inhibitors, demonstrate potential efficacy in favourably modulating lipid profiles and targeting specific components of atherogenic dyslipidaemia (AD). Combination therapies tailored to individual lipid profiles show promise to reduce residual CV risk. Conclusion: The following review aims to provide a comprehensive overview of the latest evidence on the factors driving residual CV risk and the therapeutic interventions available to treat atherogenic dyslipidaemia beyond LDL‐C reduction.
Funding Information
  • Agencia Estatal de Investigación (Grant M‐ERA‐NET‐3/PCI2023‐143431)
  • Agencia Estatal de Investigación (PID2021‐128891OB‐I00)
  • Fundació la Marató de TV3 (#202337‐ 30‐31)
  • European Cooperation in Science and Technology (CA22169)
  • Generalitat de Catalunya (2021‐SGR 01006)
  • Instituto de Salud Carlos III (PI22/01930)

This publication has 202 references indexed in Scilit: